By Fineline Cube 
The New Drug Application (NDA) for rademikibart, an anti-inflammatory monoclonal antibody (mAb) co-developed by China’s Simcere Pharmaceutical Co., Ltd. (HKG: 2096) and US-based Connect Biopharma Holdings Ltd (NASDAQ: CNTB), has been accepted for review by China’s National Medical Products Administration (NMPA). The targeted indication is atopic dermatitis (AD).
Drug Profile
Rademikibart is a human mAb targeting IL-4Rα, a common subunit for IL-4R and IL-13 receptors. It is under development to treat Th2-driven inflammatory diseases, including atopic dermatitis and asthma.-Fineline Info & Tech